The Lilly Open Innovation Drug Discovery Program (OIDD)

Posted by
Daniel Robertson
on 13 09 2013

Through OIDD, Lilly has established a network of top global research talent at academic and biotech institutions to provide them access to proprietary, in vitro phenotypic and target-based assays (PD2 and TargetD2). This partnership is supported by the program’s website portal and application, which lowers the barrier for collaborations between investigators working inside and outside the Lilly walls. Although ChemAxon tools have been foundational to this project from the start, recently Lilly has been partnering with ChemAxon to deliver additional design and property tools for OIDD investigators to use as part of this initiative.

Open slides in pdf